Chemistry and pharmacological characterization of novel nitrogen analogues of AMOP-H-OH (sazetidine-A, 6-[5-(azetidin-2-ylmethoxy)pyridin-3-yl]hex-5-yn-1- ol) as α4β2-nicotinic acetylcholine receptor-selective partial agonists

Journal of Medicinal Chemistry

Volumn 53, Issue 19, 2010, Pages 6973-6985

  Liu, Jianhua ^a   Eaton, J Brek ^b   Caldarone, Barbara ^c   Lukas, Ronald J ^b   Kozikowski, Alan P ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b Barrow Neurological Institute   (United States)

^c PSYCHOGENICS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 (1 INDOLINYL) 5 [(2 PYRROLIDINYL)METHOXY]PYRIDINE; 3 (1 INDOLYL) 5 (2 PYRROLIDINYLMETHOXY)PYRIDINE; 3 (1,3 DIHYDROISOINDOL 2 YL) 5 [(2 PYRROLIDINYL)METHOXY]PYRIDINE; 3 [(1 METHYL 2 AZETIDINYL)METHOXY] 5 (PIPERIDINYL)PYRIDINE; 3 [(1 METHYL 2 PYRROLIDINYL)METHOXY] 5 (PIPERIDINYL)PYRIDINE; 3 [(2 AZETIDINYL)METHOXY] 5 (PIPERIDINYL)PYRIDINE; 3 [(2 PYRROLIDINYL)METHOXY] 5 (MORPHOLINYL)PYRIDINE; 3 [(2 PYRROLIDINYL)METHOXY] 5 (PIPERAZINYL)PYRIDINE; 3 [(2 PYRROLIDINYL)METHOXY] 5 (PIPERIDINYL)PYRIDINE; 3 [(2 PYRROLIDINYL)METHOXY] 5 (PYRROLIDINYL)PYRIDINE; 3 [(2 PYRROLIDINYL)METHOXY] 5 BENZYLAMINOPYRIDINE; 3 [(2 PYRROLIDINYL)METHOXY] 5 BUTYLAMINOPYRIDINE; 3 [(2 PYRROLIDINYL)METHOXY] 5 DIETHYLAMINOPYRIDIN; 3 [(2 PYRROLIDINYL)METHOXY] 5 PHENYLAMINOPYRIDINE; 3 [(2 PYRROLIDINYL)METHOXY] 5 [(N ETHYL N PHENYL)AMINO]PYRIDINE; 3 [(2 PYRROLIDINYL)METHOXY] 5 [(N METHYL N BENZYL)AMINO]PYRIDINE; ANTIDEPRESSANT AGENT; NICOTINIC AGENT; NICOTINIC RECEPTOR; NICOTINIC RECEPTOR ALPHA3BETA4; NICOTINIC RECEPTOR ALPHA4BETA2; NITROGEN DERIVATIVE; PYRIDINE DERIVATIVE; SAZETIDINE A; UNCLASSIFIED DRUG; 3-((2-PYRROLIDINYL)METHOXY)-5-PHENYLAMINOPYRIDINE; AMINOPYRIDINE DERIVATIVE; AZETIDINE DERIVATIVE; LIGAND; PYRROLIDINE DERIVATIVE; SAZETIDINE-A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DEMETHYLATION; DEPRESSION; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; FORCED SWIMMING TEST; HUMAN; HUMAN CELL; IC 50; LIGAND BINDING; MOUSE; NONHUMAN; RAT; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION; ANIMAL; BAGG ALBINO MOUSE; BINDING COMPETITION; CELL LINE; CHEMISTRY; CHLOROCEBUS AETHIOPS; CRICETULUS; FOREBRAIN; HAMSTER; IN VITRO STUDY; MALE; METABOLISM; PARTIAL AGONISM; PHYSIOLOGY; RADIOASSAY; STEREOISOMERISM; SYNTHESIS;

AMINOPYRIDINES; ANIMALS; ANTIDEPRESSIVE AGENTS; AZETIDINES; BINDING, COMPETITIVE; CELL LINE; CERCOPITHECUS AETHIOPS; CRICETINAE; CRICETULUS; DRUG PARTIAL AGONISM; HUMANS; IN VITRO TECHNIQUES; LIGANDS; MALE; MICE; MICE, INBRED BALB C; PROSENCEPHALON; PYRIDINES; PYRROLIDINES; RADIOLIGAND ASSAY; RATS; RECEPTORS, NICOTINIC; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77957898423     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm100765u     Document Type: Article

References (53)

1. Romanelli, M. N.; Gratteri, P.; Guandalini, L.; Martini, E.; Bonaccini, C.; Gualtieri, F. Central nicotinic receptors: structure, function, ligands, and therapeutic potential ChemMedChem 2007, 2, 746-767
2. Gotti, C.; Clementi, F.; Fornari, A.; Gaimarri, A.; Guiducci, S.; Manfredi, I.; Moretti, M.; Pedrazzi, P.; Pucci, L.; Zoli, M. Structural and functional diversity of native brain neuronal nicotinic receptors Biochem. Pharmacol. 2009, 78, 703-711
3. Shytle, R. D.; Silver, A. A.; Lukas, R. J.; Newman, M. B.; Sheehan, D. V.; Sanberg, P. R. Nicotinic acetylcholine receptors as targets for antidepressants Mol. Psychiatry 2002, 7, 525-535
4. Fryer, J. D.; Lukas, R. J. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine J. Pharmacol. Exp. Ther. 1999, 288, 88-92
5. Fryer, J. D.; Lukas, R. J. Antidepressants noncompetitively inhibit nicotinic acetylcholine receptor function J. Neurochem. 1999, 72, 1117-1124
6. Damaj, M. I.; Carroll, F. I.; Eaton, J. B.; Navarro, H. A.; Blough, B. E.; Mirza, S.; Lukas, R. J.; Martin, B. R. Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors Mol. Pharmacol. 2004, 66, 675-682
7. Dwoskin, L. P.; Smith, A. M.; Wooters, T. E.; Zhang, Z.; Crooks, P. A.; Bardo, M. T. Nicotinic receptor-based therapeutics and candidates for smoking cessation Biochem. Pharmacol. 2009, 78, 732-743
8. Carroll, F. I.; Blough, B. E.; Mascarella, S. W.; Navarro, H. A.; Eaton, J. B.; Lukas, R. J.; Damaj, M. I. Synthesis and biological evaluation of bupropion analogues as potential pharmacotherapies for smoking cessation J. Med. Chem. 2010, 53, 2204-2214
9. Buckingham, S. D.; Jones, A. K.; Brown, L. A.; Sattelle, D. B. Nicotinic acetylcholine receptor signalling: roles in Alzheimer's disease and amyloid neuroprotection Pharmacol. Rev. 2009, 61, 39-61
10. Quik, M.; Bordia, T.; O'Leary, K. Nicotinic receptors as CNS targets for Parkinson's disease Biochem. Pharmacol. 2007, 74, 1224-1234
11. Wilens, T. E.; Decker, M. W. Neuronal nicotinic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: focus on cognition Biochem. Pharmacol. 2007, 74, 1212-1223
12. Brody, A. L. Functional brain imaging of tobacco use and dependence J. Psychiatr. Res. 2006, 40, 404-418
13. Bencan, Z.; Levin, E. D. The role of alpha7 and alpha4beta2 nicotinic receptors in the nicotine-induced anxiolytic effect in zebrafish Physiol. Behav. 2008, 95, 408-412
14. Decker, M. W.; Meyer, M. D. Therapeutic potential of neuronal nicotinic acetylcholine receptor agonists as novel analgesics Biochem. Pharmacol. 1999, 58, 917-923
15. Martin, L. F.; Freedman, R. Schizophrenia and the alpha7 nicotinic acetylcholine receptor Int. Rev. Neurobiol. 2007, 78, 225-246
16. Ochoa, E. L.; Lasalde-Dominicci, J. Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking Cell Mol. Neurobiol. 2007, 27, 609-639
17. Egleton, R. D.; Brown, K. C.; Dasgupta, P. Nicotinic acetylcholine receptors in cancer: multiple roles in proliferation and inhibition of apoptosis Trends Pharmacol. Sci. 2008, 29, 151-158
18. Jensen, A. A.; Frolund, B.; Liljefors, T.; Krogsgaard-Larsen, P. Neuronal nicotinic acetylcholine receptors: structural revelations, target identifications, and therapeutic inspirations J. Med. Chem. 2005, 48, 4705-4745
19. Chavez-Noriega, L. E.; Crona, J. H.; Washburn, M. S.; Urrutia, A.; Elliott, K. J.; Johnson, E. C. Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors h alpha 2 beta 2, h alpha 2 beta 4, h alpha 3 beta 2, h alpha 3 beta 4, h alpha 4 beta 2, h alpha 4 beta 4 and h alpha 7 expressed in Xenopus oocytes J. Pharmacol. Exp. Ther. 1997, 280, 346-356
20. Steinlein, O. K.; Bertrand, D. Neuronal nicotinic acetylcholine receptors: from the genetic analysis to neurological diseases Biochem. Pharmacol. 2008, 76, 1175-1183
21. Cassels, B. K.; Bermudez, I.; Dajas, F.; Abin-Carriquiry, J. A.; Wonnacott, S. From ligand design to therapeutic efficacy: the challenge for nicotinic receptor research Drug Discovery Today 2005, 10, 1657-1665
22. Kanne, D. B.; Tomizawa, M.; Durkin, K. A.; Casida, J. E. 6′-Methylpyrido[3,4- b ]norhomotropane: synthesis and outstanding potency in relation to the alpha4beta2 nicotinic receptor pharmacophore model Bioorg. Med. Chem. Lett. 2005, 15, 877-881
23. Bencherif, M.; Lovette, M. E.; Fowler, K. W.; Arrington, S.; Reeves, L.; Caldwell, W. S.; Lippiello, P. M. RJR-2403: a nicotinic agonist with CNS selectivity I. In vitro characterization J. Pharmacol. Exp. Ther. 1996, 279, 1413-1421 (Pubitemid 27166790)
24. Lippiello, P. M.; Bencherif, M.; Gray, J. A.; Peters, S.; Grigoryan, G.; Hodges, H.; Collins, A. C. RJR-2403: a nicotinic agonist with CNS selectivity II. In vivo characterization J. Pharmacol. Exp. Ther. 1996, 279, 1422-1429 (Pubitemid 27166791)
25. Sullivan, J. P.; Donnelly-Roberts, D.; Briggs, C. A.; Anderson, D. J.; Gopalakrishnan, M.; Piattoni-Kaplan, M.; Campbell, J. E.; McKenna, D. G.; Molinari, E.; Hettinger, A. M.; Garvey, D. S.; Wasicak, J. T.; Holladay, M. W.; Williams, M.; Arneric, S. P. A-85380 [3-(2(S)-azetidinylmethoxy) pyridine]: in vitro pharmacological properties of a novel, high affinity alpha 4 beta 2 nicotinic acetylcholine receptor ligand Neuropharmacology 1996, 35, 725-734
26. Bunnelle, W. H.; Tietje, K. R.; Frost, J. M.; Peters, D.; Ji, J.; Li, T.; Scanio, M. J.; Shi, L.; Anderson, D. J.; Dyhring, T.; Gronlien, J. H.; Ween, H.; Thorin-Hagene, K.; Meyer, M. D. Octahydropyrrolo[3,4- c ]pyrrole: a diamine scaffold for construction of either alpha4beta2 or alpha7-selective nicotinic acetylcholine receptor (nAChR) ligands. Substitutions that switch subtype selectivity J. Med. Chem. 2009, 52, 4126-4141
27. Lloyd, G. K.; Williams, M. Neuronal nicotinic acetylcholine receptors as novel drug targets J. Pharmacol. Exp. Ther. 2000, 292, 461-467
28. Davis, J. B.; Bountra, C.; Richardson, J. Perspectives of Alzheimer's disease treatments Handb. Clin. Neurol. 2008, 89, 273-290
29. Guandalini, L.; Martini, E.; Dei, S.; Manetti, D.; Scapecchi, S.; Teodori, E.; Romanelli, M. N.; Varani, K.; Greco, G.; Spadola, L.; Novellino, E. Design of novel nicotinic ligands through 3D database searching Bioorg. Med. Chem. 2005, 13, 799-807
30. Guandalini, L.; Martini, E.; Gratteri, P.; Ghelardini, C.; Varani, K.; Romanelli, M. N. Design, synthesis and binding affinity of new nicotinic ligands ARKIVOC 2006, VIII, 50-65
31. Meyer, M. D. Neuronal nicotinic acetylcholine receptors as a target for the treatment of neuropathic pain Drug Dev. Res. 2006, 67, 355-359
32. Rueter, L. E.; Anderson, D. J.; Briggs, C. A.; Donnelly-Roberts, D. L.; Gintant, G. A.; Gopalakrishnan, M.; Lin, N. H.; Osinski, M. A.; Reinhart, G. A.; Buckley, M. J.; Martin, R. L.; McDermott, J. S.; Preusser, L. C.; Seifert, T. R.; Su, Z.; Cox, B. F.; Decker, M. W.; Sullivan, J. P. ABT-089: pharmacological properties of a neuronal nicotinic acetylcholine receptor agonist for the potential treatment of cognitive disorders CNS Drug Rev. 2004, 10, 167-182
33. Cosford, N. D.; Bleicher, L.; Herbaut, A.; McCallum, J. S.; Vernier, J. M.; Dawson, H.; Whitten, J. P.; Adams, P.; Chavez-Noriega, L.; Correa, L. D.; Crona, J. H.; Mahaffy, L. S.; Menzaghi, F.; Rao, T. S.; Reid, R.; Sacaan, A. I.; Santori, E.; Stauderman, K. A.; Whelan, K.; Lloyd, G. K.; McDonald, I. A. (S)-(-)-5-Ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine maleate (SIB-1508Y): a novel anti-Parkinsonian agent with selectivity for neuronal nicotinic acetylcholine receptors J. Med. Chem. 1996, 39, 3235-3237
34. Xiao, Y.; Fan, H.; Musachio, J. L.; Wei, Z. L.; Chellappan, S. K.; Kozikowski, A. P.; Kellar, K. J. Sazetidine-A, a novel ligand that desensitizes alpha4beta2 nicotinic acetylcholine receptors without activating them Mol. Pharmacol. 2006, 70, 1454-1460
35. Zwart, R.; Carbone, A. L.; Moroni, M.; Bermudez, I.; Mogg, A. J.; Folly, E. A.; Broad, L. M.; Williams, A. C.; Zhang, D.; Ding, C.; Heinz, B. A.; Sher, E. Sazetidine-A is a potent and selective agonist at native and recombinant alpha 4 beta 2 nicotinic acetylcholine receptors Mol. Pharmacol. 2008, 73, 1838-1843
36. Kozikowski, A. P.; Eaton, J. B.; Bajjuri, K. M.; Chellappan, S. K.; Chen, Y.; Karadi, S.; He, R.; Caldarone, B.; Manzano, M.; Yuen, P. W.; Lukas, R. J. Chemistry and pharmacology of nicotinic ligands based on 6-[5-(azetidin-2- ylmethoxy)pyridin-3-yl]hex-5-yn-1-ol (AMOP-H-OH) for possible use in depression ChemMedChem 2009, 4, 1279-1291
37. Gatto, G. J.; Bohme, G. A.; Caldwell, W. S.; Letchworth, S. R.; Traina, V. M.; Obinu, M. C.; Laville, M.; Reibaud, M.; Pradier, L.; Dunbar, G.; Bencherif, M. TC-1734: an orally active neuronal nicotinic acetylcholine receptor modulator with antidepressant, neuroprotective and long-lasting cognitive effects CNS Drug Rev. 2004, 10, 147-166
38. Wei, Z. L.; Xiao, Y.; Yuan, H.; Baydyuk, M.; Petukhov, P. A.; Musachio, J. L.; Kellar, K. J.; Kozikowski, A. P. Novel pyridyl ring C5 substituted analogues of epibatidine and 3-(1-methyl-2(S)-pyrrolidinylmethoxy)pyridine (A-84543) as highly selective agents for neuronal nicotinic acetylcholine receptors containing beta2 subunits J. Med. Chem. 2005, 48, 1721-1724
39. Ortiz de Montellano, P. R.; Kunze, K. L. Self-catalyzed inactivation of hepatic cytochrome P-450 by ethynyl substrates J. Biol. Chem. 1980, 255, 5578-5585
40. Lin, N. H.; Gunn, D. E.; Li, Y.; He, Y.; Bai, H.; Ryther, K. B.; Kuntzweiler, T.; Donnelly-Roberts, D. L.; Anderson, D. J.; Campbell, J. E.; Sullivan, J. P.; Arneric, S. P.; Holladay, M. W. Synthesis and structure-activity relationships of pyridine-modified analogs of 3-[2-((S)-pyrrolidinyl)methoxy]pyridine, A-84543, a potent nicotinic acetylcholine receptor agonist Bioorg. Med. Chem. Lett. 1998, 8, 249-254
41. Holladay, M. W.; Bai, H.; Li, Y.; Lin, N. H.; Daanen, J. F.; Ryther, K. B.; Wasicak, J. T.; Kincaid, J. F.; He, Y.; Hettinger, A. M.; Huang, P.; Anderson, D. J.; Bannon, A. W.; Buckley, M. J.; Campbell, J. E.; Donnelly-Roberts, D. L.; Gunther, K. L.; Kim, D. J.; Kuntzweiler, T. A.; Sullivan, J. P.; Decker, M. W.; Arneric, S. P. Structure-activity studies related to ABT-594, a potent nonopioid analgesic agent: effect of pyridine and azetidine ring substitutions on nicotinic acetylcholine receptor binding affinity and analgesic activity in mice Bioorg. Med. Chem. Lett. 1998, 8, 2797-2802
42. Porsolt, R. D.; Bertin, A.; Jalfre, M. Behavioral despair in mice: a primary screening test for antidepressants Arch. Int. Pharmacodyn. Ther. 1977, 229, 327-336
43. Wolfe, J. P.; Wagaw, S.; Marcoux, J. F.; Buchwald, S. L. Rational development of practical catalysts for aromatic carbon-nitrogen bond formation Acc. Chem. Res. 1998, 31, 805-818
44. Surry, D. S.; Buchwald, S. L. Biaryl phosphane ligands in palladium-catalyzed amination Angew. Chem., Int. Ed. Engl. 2008, 47, 6338-6361
45. Nicolazzo, J. A.; Charman, S. A.; Charman, W. N. Methods to assess drug permeability across the blood-brain barrier J. Pharm. Pharmacol. 2006, 58, 281-293
46. Fan, Y.; Unwalla, R.; Denny, R. A.; Di, L.; Kerns, E. H.; Diller, D. J.; Humblet, C. Insights for predicting blood-brain barrier penetration of CNS targeted molecules using QSPR approaches J. Chem. Inf. Model. 2010, 50, 1123-1133
47. Mavandadi, F.; Pilotti, A. The impact of microwave-assisted organic synthesis in drug discovery Drug Discovery Today 2006, 11, 165-174
48. Forman, S. A.; Firestone, L. L.; Miller, K. W. Is agonist self-inhibition at the nicotinic acetylcholine receptor a nonspecific action? Biochemistry 1987, 26, 2807-2814
49. Arias, H. R. Agonist self-inhibitory binding site of the nicotinic acetylcholine receptor J. Neurosci. Res. 1996, 44, 97-105
50. Buckley, M. J.; Surowy, C.; Meyer, M.; Curzon, P. Mechanism of action of A-85380 in an animal model of depression Prog. Neuropsychopharmacol. Biol. Psychiatry 2004, 28, 723-730
51. Lukas, R. J.; Fryer, J. D.; Eaton, J. B.; Gentry, C. L. Some methods for studies of nicotinic acetylcholine receptor pharmacology. In Nicotinic Receptors and the Nervous System; Levin, E. D., Ed.; CRC Press: Boca Raton, FL, 2002; pp 3 - 27.
52. Lukas, R. J.; Norman, S. A.; Lucero, L. Characterization of Nicotinic Acetylcholine Receptors Expressed by Cells of the SH-SY5Y Human Neuroblastoma Clonal Line Mol. Cell Neurosci. 1993, 4, 1-12
53. Eaton, J. B.; Peng, J. H.; Schroeder, K. M.; George, A. A.; Fryer, J. D.; Krishnan, C.; Buhlman, L.; Kuo, Y. P.; Steinlein, O.; Lukas, R. J. Characterization of human alpha 4 beta 2-nicotinic acetylcholine receptors stably and heterologously expressed in native nicotinic receptor-null SH-EP1 human epithelial cells Mol. Pharmacol. 2003, 64, 1283-1294